Results 111 to 120 of about 35,110 (216)

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 540-550, March 2025.
ABSTRACT We employed a mechanistic learning approach, integrating on‐treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post‐progression survival (PPS)—the duration from the time of documented disease progression to death—and overall survival (OS) in Head and Neck Squamous Cell ...
Kevin Atsou   +4 more
wiley   +1 more source

Overcoming cetuximab resistance in Ewing's sarcoma by inhibiting lactate dehydrogenase-A

open access: yesMolecular Medicine Reports, 2016
Ewing's sarcoma, the second most common type of malignant bone tumor, generally occurs in children and young adults. The current treatment of Ewing's sarcoma comprises systemic anti‑cancer chemotherapy with complete surgical resection. However, the majority of patients with Ewing's sarcoma develop resistance to chemotherapy.
Jiaxin, Fu   +5 more
openaire   +3 more sources

Management of Treatment Resistant EGFR Inhibitor‐Induced Papulopustular Exanthema With Isotretinoin and Dapsone

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Epidermal growth factor receptor inhibitors (EGFRi) commonly cause papulopustular exanthemas that may compromise the success of cancer therapy. While tetracyclines are first‐line treatment, data on alternative systemic agents for refractory cases remain limited.
Ishana Dixit   +2 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

open access: yes, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada   +119 more
core   +1 more source

Antitumor activity of an anti-CD98 antibody. [PDF]

open access: yes, 2015
CD98 is expressed on several tissue types and specifically upregulated on fast-cycling cells undergoing clonal expansion. Various solid (e.g., nonsmall cell lung carcinoma) as well as hematological malignancies (e.g., acute myeloid leukemia) overexpress ...
Cairns, Belinda   +11 more
core   +1 more source

Inhibition of P‐glycoprotein using photoimmunotherapy in peritoneal metastasis mouse model

open access: yesPhotochemistry and Photobiology, EarlyView.
Photoimmunotherapy (PIT) using photoimmunoconjugates (PICs) can inhibit the function of the ATP‐binding cassette (ABC) transporter P‐glycoprotein (P‐gp) in a mouse model of peritoneal carcinomatosis. Sterile‐filtered PIC was administered in vivo via intraperitoneal (IP) injection 20 days after IP tumor cell implantation of P‐gp‐overexpressing NCI/ADR ...
Kaitlyn A. Moore   +6 more
wiley   +1 more source

Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma

open access: yesFrontiers in Oncology
Immunotherapy is the first-line option for treating advanced cutaneous squamous cell carcinoma (cSCC). However, up to half of patients experience no benefit and treatment resistance, warranting newer therapeutic approaches.
Renee Morecroft   +6 more
doaj   +1 more source

Differential Targeting of Stem Cells and Differentiated Glioblastomas by NK Cells. [PDF]

open access: yes, 2015
We have recently shown that Natural Killer (NK) cells control survival and differentiation of Cancer Stem-like Cells (CSCs) through two distinct phenotypes of cytotoxic and anergic NK cells, respectively. In this report, brain CSCs and their serum and NK
Bui, Vickie T   +6 more
core   +1 more source

Light‐Triggered Antibody‐Photosensitizer Conjugates Disrupt P‐Glycoprotein Function to Reverse Multidrug Resistance

open access: yesAdvanced Therapeutics, Volume 9, Issue 4, April 2026.
Advanced ovarian cancer has a poor prognosis largely due to chemoresistance driven by ATP‐binding cassette (ABC) drug efflux transporters, especially P‐glycoprotein (P‐gp, or ABCB1). While photodynamic therapy (PDT) with FDA‐approved benzoporphyrin derivative (BPD) can inhibit ABC transporters, BPD alone lacks cancer selectivity.
Kathryn L. McNaughton   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy